The National Agency for Food and Drug Administration and Control (NAFDAC) has emerged as a vanguard for regulatory excellence in Africa, setting a transformative standard that many peer nations are now looking to emulate. This shift in the Nigerian regulatory landscape was recently placed under the international spotlight when the Director-General of NAFDAC, Prof. Mojisola Adeyeye, delivered a keynote address at the Global Health Perspectives series hosted by the Takemi Program in International Health at the Harvard T.H. Chan School of Public Health. Her presentation not only cataloged the agency’s technical achievements but also articulated a strategic framework for how developing nations can overcome systemic bottlenecks to ensure the safety, efficacy, and quality of pharmaceutical products.

A Chronology of Institutional Advancement

To understand the significance of NAFDAC’s current standing, one must look at its trajectory since 2017. When Prof. Adeyeye assumed leadership, the agency was grappling with significant operational deficits, notably ranking below the World Health Organization (WHO) Global Benchmarking Tool (GBT) Maturity Level 1. This classification indicated a system that was largely non-functional or unable to provide oversight for the safety and quality of medical products.

The subsequent years marked a period of aggressive institutional reform. By 2019, the agency had reached Maturity Level 3, a significant milestone that signifies a stable, well-functioning, and integrated regulatory system. This progression was not merely administrative; it required a complete overhaul of laboratory infrastructure, the implementation of rigorous quality management systems, and a cultural shift toward evidence-based decision-making. The pursuit of Level 4—the highest tier of the WHO benchmarking—is currently the agency’s primary strategic objective, alongside the pursuit of status as a WHO-Listed Authority (WLA).

The Five Pillars of Regulatory Transformation

During her lecture at Harvard, Prof. Adeyeye identified five core strategic pillars that facilitated this turnaround. These areas of reform provide a template for other African national regulatory authorities (NRAs) seeking to professionalize their operations:

1. Enhanced Governance Structures: By streamlining internal processes and removing bureaucratic silos, NAFDAC improved its internal accountability. This involved clear delineation of roles, the introduction of merit-based management, and the alignment of agency goals with international regulatory standards.
2. Scientific and Quality Capabilities: The agency invested heavily in upgrading its laboratory infrastructure. This led to the WHO prequalification of its central laboratory, an essential step in ensuring that test results are internationally recognized and reliable.
3. Robust Surveillance Systems: Monitoring the post-market supply chain is notoriously difficult in a market as large and complex as Nigeria’s. By strengthening enforcement activities and adopting sophisticated tracking technologies, NAFDAC has significantly curtailed the entry of substandard and falsified medical products.
4. Digital Transformation: Perhaps the most visible change for stakeholders has been the digitalization of regulatory processes. Today, approximately 90 percent of NAFDAC’s operations—ranging from product registration to permit issuance—are handled through digital platforms. This shift has not only reduced the potential for corruption but has also increased the efficiency of drug approval timelines.
5. Strategic Partnerships: NAFDAC has actively cultivated relationships with international bodies such as the WHO, the United States Pharmacopeia (USP), and various global health organizations. These partnerships have provided the technical assistance and capacity-building required to meet global benchmarks.

Supporting Data and Regulatory Implications

The impact of these reforms is evident in the agency’s ISO 9001 certification, which confirms that NAFDAC’s quality management system meets international requirements for consistency and continuous improvement. Furthermore, the agency’s laboratory capacity expansion has enabled it to test a wider array of pharmaceutical products, from vaccines to complex biologics, reducing the reliance on external testing facilities.

From a public health perspective, the implications are profound. In a region where substandard and falsified medications are estimated to contribute significantly to morbidity and mortality, a strong regulator serves as the first line of defense. According to data from the WHO, a significant percentage of medicines in low- and middle-income countries are either substandard or falsified, leading to treatment failures and the development of drug-resistant pathogens. By achieving WHO Maturity Level 3 and aiming for Level 4, NAFDAC is effectively closing the regulatory gap that allows these products to thrive.

Balancing Local Manufacturing and Global Standards

A critical point of discussion during Prof. Adeyeye’s address was the delicate balance between fostering local pharmaceutical manufacturing and maintaining strict safety standards. Nigeria’s reliance on imported active pharmaceutical ingredients (APIs) and finished products remains a challenge to economic sovereignty.

Adeyeye emphasized that NAFDAC’s role is to act as a facilitator rather than a barrier. By providing technical guidance to local manufacturers, the agency is helping them meet Good Manufacturing Practice (GMP) standards. This dual approach—enforcing safety while supporting local industry growth—is essential for regional health security. By fostering a local environment where quality medicines can be produced, Nigeria reduces its dependence on potentially volatile global supply chains.

Global Perspectives on Regulatory Cooperation

The Harvard platform highlighted that regulatory reform is not a solitary endeavor. The lecture underscored that the future of African health security rests on the ability of national regulatory authorities to cooperate. Through the African Medicines Agency (AMA) initiative, NAFDAC’s model of reform is serving as a catalyst for regional harmonization. If African countries can synchronize their regulatory requirements, they can create a larger, more attractive market for high-quality manufacturers, further discouraging the circulation of counterfeit goods.

The Path Forward: Challenges and Opportunities

Despite the successes, the road to Level 4 maturity is fraught with challenges. The agency must contend with a rapidly evolving global pharmaceutical landscape, characterized by the rise of personalized medicine and digital health. Maintaining financial accountability remains paramount, as the agency must secure sustainable funding to support its laboratory operations and human capital development.

Prof. Adeyeye’s call for evidence-based decision-making is a direct response to the pressures faced by modern regulators. As the complexity of medicines increases, regulators can no longer rely on manual processes or antiquated surveillance methods. The investment in staff training and the adoption of artificial intelligence in regulatory oversight will likely be the next frontier for NAFDAC.

Conclusion: A Legacy of Reform

The progress made by NAFDAC under Prof. Mojisola Adeyeye offers a compelling case study for public policy experts and global health practitioners. It demonstrates that with the right combination of political will, international collaboration, and a commitment to digital modernization, even the most challenged regulatory agencies can achieve global recognition.

As NAFDAC works toward becoming a WHO-Listed Authority, it is not merely chasing a certification; it is solidifying a system that protects millions of lives. The lessons from its journey—prioritizing transparency, investing in technical human capital, and embracing digital transformation—resonate far beyond the borders of Nigeria, providing a clear map for the strengthening of pharmaceutical regulation across the African continent. The ultimate goal remains a landscape where every citizen has access to safe, effective, and affordable medicines, a reality that is now more attainable than ever due to these sustained institutional reforms.